What changed
EMA recommended EU authorization for Foundayo and described orforglipron as a small non-peptide molecule.
What the evidence does not settle
CHMP opinion was intermediate, awaiting a Commission decision on that date; national pricing/reimbursement are separate.
Evidence record
Event date: 2026-10-16. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.